Related Experiment Videos
Summary
Phenformin, an antifibrinopathic agent, improved blood sugar control and reduced cardiovascular issues in diabetes and atherosclerosis patients. Its benefits are linked to its positive effects on blood clotting and fibrinolysis.
Area of Science:
- Pharmacology
- Hematology
- Endocrinology
Background:
- Atherosclerosis and diabetes mellitus share complex pathophysiological links.
- Fibrinopathic processes are implicated in the development of these conditions.
- Phenformin's potential therapeutic effects beyond glycemic control warrant investigation.
Purpose of the Study:
- To evaluate the effects of phenformin on glycemic control, lipid profiles, and coagulation parameters.
- To assess the impact of phenformin on cardiovascular complications in patients with maturity onset diabetes and atherosclerosis.
- To explore the relationship between phenformin's antifibrinopathic properties and its clinical benefits.
Main Methods:
- A prospective study involving patients with maturity onset diabetes and/or atherosclerosis.
- Treatment with phenformin over a 14-18 month period.
- Monitoring of blood sugar, serum triglyceride, thrombin time, and euglobulin clot lysis time.
Main Results:
- Phenformin demonstrated antifibrinopathic properties by prolonging thrombin time and enhancing fibrinolysis.
- A direct correlation was observed between phenformin's hypoglycemic effect and its antifibrinopathic action.
- Significant reductions in plasma lipids, fewer cardiovascular complications, and improved anginal symptoms were noted.
Conclusions:
- Phenformin exerts beneficial metabolic, hematological, and clinical effects in maturity onset diabetes and atherosclerosis.
- These benefits are likely mediated by phenformin's influence on the thrombin-fibrinogen reaction.
- The findings support a primary role for fibrinopathic pathogenesis in these conditions.